• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,763.91 261.79
( 0.34%)
Global Indices
Nasdaq
52,921.07 594.83
(1.14%)
Dow Jones
7,504.24 0.01
(0.00%)
Hang Seng
69,733.68 1,000.53
(1.46%)
Nikkei 225
10,673.34 20.47
(0.19%)
Forex
USD-INR
95.28 0.28
(0.30%)
EUR-INR
108.75 0.54
(0.50%)
GBP-INR
126.99 1.06
(0.84%)
JPY-INR
0.59 0.01
(0.97%)

EQUITY - MARKET SCREENER

Khadim India Ltd
Industry :  Leather / Leather Products
BSE Code
ISIN Demat
Book Value()
540775
INE834I01025
90.9266017
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KHADIM
48.02
200.32
EPS(TTM)
Face Value()
Div & Yield %
2.27
10
0
 

Concord Biotech rallies after USFDA approval for Tofacitinib tablets
Jun 10,2026
Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular-course juvenile idiopathic arthritis.

According to market estimates, the US market size for Tofacitinib tablets across both strengths is approximately $500 million. The approval is expected to enable the company to tap this market opportunity, expand its product portfolio, and support its long-term growth strategy in the US and other international markets.

Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations. It has a presence in more than 70 countries worldwide.

The company’s consolidated net profit declined 36.75% to Rs 88.79 crore on a 24.15% drop in revenue from operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25.